Ultram

Item	Count		Retail	Price	Order
Ultram 50 mg	30	tablets	$111.30	$92.75
Ultram 50 mg	60	tablets	$159.30	$132.75
Ultram 50 mg	90	tablets	$207.30	$172.75

DRUG ABUSE AND DEPENDENCE :

Tramadol has a potential to cause psychic and physical dependence of the morphone-type. The drug has been associated with craving, drug-seeking behavior and tolerance development. Cases of abuse and dependence on Tramadol have been reported.

Tramadol should not be used in opioid-dependent patients. Tramadol can reinitiate physical dependence in patients that have been previously dependent or chronically using other opioids. In patients with a tendency to drug abuse, a history of drug dependence, or are chronically using opioids, treatment with Tramadol is not recommended.

Tramadol AND SEIZURES :

Seizure Risk : Seizures have been reported in patients receiving Tramadol within the recommended dosage range. Concomitant use of Tramadol increases the seizure risk in patients taking:

Selective serotonin reuptake inhibitors (SSRI antidepressants or anoretics -phentermine), Tricyclic antidepressants and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.)

Opioids. 

MAO inhibitors 

Neuroleptics

Any drugs that reduce the seizure threshold

Epilepsy

Tramadol AND DROWZINESS :

Tramadol may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.

Tramadol should not be taken with alcohol containing beverages.

Tramadol should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.

Tramadol AND PREGNANCY :

Tramadol should not be used in pregnant women or nursing mothers, safe use in pregnancy has not been established.

Chronic use during pregnancy may lead to physical dependence and post-pregnancy withdrawal symptoms in the newborn.

Tramadol has been shown to cross the placenta. Nonetheless, the effect of Tramadol, if any, on the later growth, development, and functional maturation of the child is unknown.

OVERDOSAGE :

Serious potential consequences of over dosage are respiratory depression and seizure.

FREQUENTLY ASKED QUESTIONS ABOUT ULTRAM

Ultram acts on the central nervous system and unlike codeine and its derivative medications is a totally synthetic analgesic compound. Although Ultram 's mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: the binding of the parent Ultram compound and its metabolite to opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin by nerves located within the central nervous system. Ultram -induced analgesia is only partially reversed by the opiate antagonist naloxone in several animal tests.

Ultram has been shown to inhibit reuptake of norepinephrine and serotonin in vitro. These mechanisms may contribute independently to the overall analgesic profile of Ultram . Analgesia in humans begins approximately within one hour after administration of Ultram and reaches a peak in approximately two to three hours.

HOW EFFECTIVE IS ULTRAM?

Ultram has been given in single oral doses of 50, 75, 100, 150 and 200 mg to patients with pain following surgical procedures and pain following oral surgery (extraction of impacted molars). In single-dose models of pain following oral surgery, pain relief with Ultram was demonstrated in some patients at doses of 50 mg and 75 mg. A dose of 100 mg of Ultram tended to provide analgesia superior to codeine sulfate 60 mg, but it was not effective as the combination of aspirin 650 mg with codeine phosphate 60 mg. In single-dose models of pain following surgical procedures, 150 mg of Ultram provided analgesia generally comparable to the combination of acetaminophen 650 mg with propoxyphene napsylate 100 mg, with a tendency toward later peak effect.

Ultram has been studied in three long-term controlled trials involving a total of 820 patients, with 530 patients receiving Ultram . Patients with a variety of chronic painful conditions were studied in double-blind trials of one to three months duration. Average daily doses of approximately 250 mg of Ultram in divided doses were generally comparable with five doses of acetaminophen 300 mg with codeine phosphate 30 mg (Tylenol with Codeine #3) daily, five doses of aspirin 325 mg with codeine phosphate 30 mg daily, or two to three doses of acetaminophen 500 mg with oxycodone hydrochloride 5 mg (Tylox) daily.

HOW DO I USE ULTRAM?

For the treatment of painful conditions Ultram 50 mg to 100 mg can be administered as needed for relief every four to six hours, not to exceed 400 mg per day. For moderate pain Ultram 50 mg may be adequate as the initial dose, and for more severe pain, Ultram 100 mg is usually more effective as the initial dose.

Individualization of Dose:

• Patients 65 to 75 years of age: No Ultram dose adjustment is necessary.
• Patients over 75 years old: No more then 300 mg/day of Ultram in divided doses.
• Patients with kidney impairment: The dosing interval of Ultram should be increased to 12 hours with a maximum daily dose of 200 mg.
• Dialysis patients: These patients can receive their regular dose of Ultram on the day of dialysis.
• Patients with cirrhosis: Recommended dosage of Ultram 50 mg every 12 hours.
• Patients receiving chronic carbamazepine: Doses up to 800 mg daily of Ultram may be required, this is up to twice the recommended dose of Ultram .

ADVERSE REACTIONS WITH ULTRAM:

Ultram was administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant pain. Of these patients, 375 were 65 years old or older. TABLE 2 reports the cumulative incidence rate of adverse reactions with Ultram by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days). The most frequently reported events on Ultram were in the central nervous system and gastrointestinal system. Although the reactions listed in the table are felt to be probably related to Ultram administration, the reported rates also include some events that may have been due to underlying disease or concomitant medication. The overall incidence rates of adverse experiences in these trials were similar for Ultram and the active control groups, acetaminophen 300 mg with codeine phosphate 30 mg, and aspirin 325 mg with codeine phosphate 30 mg. (TABLE 2)

DRUG ABUSE AND DEPENDENCE WITH ULTRAM:

Ultram has a potential to cause psychic and physical dependence of the morphone-type. The drug has been associated with craving, drug-seeking behavior and tolerance development. Cases of abuse and dependence on Ultram have been reported.

Ultram should not be used in opioid-dependent patients. Ultram can reinitiate physical dependence in patients that have been previously dependent or chronically using other opioids. In patients with a tendency to drug abuse, a history of drug dependence, or are chronically using opioids, treatment with Ultram is not recommended.

ULTRAM AND SEIZURES:

Seizure Risk: Seizures have been reported in patients receiving Ultram within the recommended dosage range. Concomitant use of Ultram increases the seizure risk in patients taking:

• Selective serotonin reuptake inhibitors (SSRI antidepressants or anoretics -phentermine) and Ultram ,
• Tricyclic antidepressants and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.) and Ultram
• Opioids and Ultram
• MAO inhibitors and Ultram
• Neuroleptics and Ultram
• Any drugs that reduce the seizure threshold and Ultram
• Epilepsy and Ultram

ULTRAM AND DROWZINESS:

• Ultram may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
• Ultram should not be taken with alcohol containing beverages.
• Ultram should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.

ULTRAM AND PREGNANCY:

• Ultram should not be used in pregnant women or nursing mothers, safe use in pregnancy has not been established.
• Chronic use of Ultram during pregnancy may lead to physical dependence and post-pregnancy withdrawal symptoms in the newborn.
• Ultram has been shown to cross the placenta. Nonetheless, the effect of Ultram , if any, on the later growth, development, and functional maturation of the child is unknown.

OVERDOSAGE:

Serious potential consequences of Ultram over dosage are respiratory depression and seizure.

ADDITIONAL QUESTIONS:

Not every question can be addressed in this FAQ page. If any additional questions remain we suggest you contact your local physician.

Buy ultram - Buy Low Cost ultram - ultram Online